Zhengli Xu

Abstract Acute myeloid leukemia (AML) is a rapidly progressive malignancy with poor prognosis. To date, chimeric antigen receptor (CAR) T-cell therapy in AML has been limited by the lack of antigens with high specificity for AML cells. Here, we developed a synthetic T-cell receptor and antigen receptor-T (STAR-T) cell therapy targeting LILRB4, an immunosuppressive receptor highly expressed on monocytic AML blasts but not on hematopoietic stem cells.

To the editor, Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder for which allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option [1]. In China, haploidentical donor (HID) HSCT is widely used because many patients lack a matched sibling donor (MSD), and timely unrelated donor access can be challenging; outcomes after HID HSCT are comparable to those after MSD transplantation in SAA [2].

CONFLICT OF INTEREST STATEMENT The authors have no conflicts of interest to disclose. DATA AVAILABILITY STATEMENT The datasets analysed during the current study are available from the corresponding authors on reasonable request. Supporting Information Filename Description bjh70259-sup-0001-TableS1.docxWord 2007 document , 23.7 KB Table S1. REFERENCES 1, , , , , , et al.